Giulia Vannucchi1, Gabriele Masi2, Cristina Toni3, Liliana Dell'Osso1, Andreas Erfurth4, Giulio Perugi5. 1. Department of Clinical and Experimental Medicine, Psychiatry Unit, University of Pisa, Italy. 2. IRCCS Stella Maris, Scientific Institute of Child Neurology and Psychiatry, Via dei Giacinti 2, 56018 Calambrone (Pisa), Italy. 3. Institute of Behavioural Sciences "G. De Lisio", Via di Pratale 3, 56100 Pisa, Italy. 4. Otto Wagner Psychiatric Hospital of Vienna, Head of Department VI, Vienna, Austria. 5. Department of Clinical and Experimental Medicine, Psychiatry Unit, University of Pisa, Institute of Behavioral Sciences "G. De Lisio", Via Roma, 67, 56100 Pisa, Italy. Electronic address: giulio.perugi@med.unipi.it.
Abstract
BACKGROUND: Asperger׳s Syndrome (AS) is a neurodevelopmental disorder included in the Autism Spectrum (ASD). The current literature shows growing evidence of a high rate of comorbidity between AS and other psychiatric disorders, particularly Bipolar Disorder (BD). We reviewed available epidemiological and clinical data on BD-AS comorbidity and its diagnostic and therapeutic implications METHODS: A systematic review of the literature was conducted through PubMed, Scopus and Psych-Info using combinations of the following search terms: Asperger׳s Syndrome, Bipolar Disorder, depression, mood disorder, psychiatric comorbidity, treatment, mood stabilizers, anticonvulsants, antipsychotics, and antidepressants. RESULTS: BD prevalence in adults with AS ranges from 6% to 21.4% of the cases. Relatives of patients with AS showed a doubled risk of being affected by BD and a BD prevalence near to 10%. When comorbid with AS, BD assumes peculiar features which might shape its under-recognition or misdiagnosis (especially schizophrenia when psychotic symptoms are prominent). Although controlled data on pharmacological treatments in BD-AS comorbidity are substantially lacking, information is derived by open observations, case series and chart reviews. Mood stabilizers should be considered the first choice, and antipsychotics, especially second generation drugs (SGA) with 5-HT2a antagonism, have been shown useful in controlling psychotic and behavioral symptoms and improving social withdrawal. Some evidence of efficacy for the treatment of anxiety, obsessive-compulsive symptoms and depression is reported for SSRI antidepressants. The use of these drugs should be carefully monitored, because activation with hypomanic or manic switches is reported up to 54% of the treated subjects. CONCLUSION: BD in AS patients is frequent, usually it onsets during adolescence and is often characterized by atypical presentation, making its correct identification particularly difficult. A correct diagnosis of BD in AS individuals has relevant implications on the choice of adequate psychopharmacological, psycho-social and rehabilitative treatments.
BACKGROUND: Asperger׳s Syndrome (AS) is a neurodevelopmental disorder included in the Autism Spectrum (ASD). The current literature shows growing evidence of a high rate of comorbidity between AS and other psychiatric disorders, particularly Bipolar Disorder (BD). We reviewed available epidemiological and clinical data on BD-AS comorbidity and its diagnostic and therapeutic implications METHODS: A systematic review of the literature was conducted through PubMed, Scopus and Psych-Info using combinations of the following search terms: Asperger׳s Syndrome, Bipolar Disorder, depression, mood disorder, psychiatric comorbidity, treatment, mood stabilizers, anticonvulsants, antipsychotics, and antidepressants. RESULTS: BD prevalence in adults with AS ranges from 6% to 21.4% of the cases. Relatives of patients with AS showed a doubled risk of being affected by BD and a BD prevalence near to 10%. When comorbid with AS, BD assumes peculiar features which might shape its under-recognition or misdiagnosis (especially schizophrenia when psychotic symptoms are prominent). Although controlled data on pharmacological treatments in BD-AS comorbidity are substantially lacking, information is derived by open observations, case series and chart reviews. Mood stabilizers should be considered the first choice, and antipsychotics, especially second generation drugs (SGA) with 5-HT2a antagonism, have been shown useful in controlling psychotic and behavioral symptoms and improving social withdrawal. Some evidence of efficacy for the treatment of anxiety, obsessive-compulsive symptoms and depression is reported for SSRI antidepressants. The use of these drugs should be carefully monitored, because activation with hypomanic or manic switches is reported up to 54% of the treated subjects. CONCLUSION: BD in AS patients is frequent, usually it onsets during adolescence and is often characterized by atypical presentation, making its correct identification particularly difficult. A correct diagnosis of BD in AS individuals has relevant implications on the choice of adequate psychopharmacological, psycho-social and rehabilitative treatments.
Authors: Fabrice Berna; Anja S Göritz; Johanna Schröder; Romain Coutelle; Jean-Marie Danion; Christine V Cuervo-Lombard; Steffen Moritz Journal: J Autism Dev Disord Date: 2016-08
Authors: Xenia Borue; Carla Mazefsky; Brian T Rooks; Michael Strober; Martin B Keller; Heather Hower; Shirley Yen; Mary Kay Gill; Rasim S Diler; David A Axelson; Benjamin I Goldstein; Tina R Goldstein; Neal Ryan; Fangzi Liao; Jeffrey I Hunt; Daniel P Dickstein; Boris Birmaher Journal: J Am Acad Child Adolesc Psychiatry Date: 2016-10-04 Impact factor: 8.829
Authors: Felicity V Larson; Adam P Wagner; Katharine Chisholm; Renate L E P Reniers; Stephen J Wood Journal: Front Psychiatry Date: 2020-07-24 Impact factor: 4.157
Authors: Ewelina Rydzewska; Laura Anne Hughes-McCormack; Christopher Gillberg; Angela Henderson; Cecilia MacIntyre; Julie Rintoul; Sally-Ann Cooper Journal: BMJ Open Date: 2018-09-01 Impact factor: 2.692